Zhangcan

Dr. Zhang is a professor in the State Key Laboratory of Natural Medicines at China Pharmaceutical University (CPU), and has served as the director of the Center of Advanced Pharmaceuticals and Biomaterials at CPU. She received her Ph.D. degree in Polymer Chemistry and Physics from Nanjing University in 2003. She has received special government allowances from the State Council, been selected as the American Institute for Medical and Biological Engineering Fellow (AIMBE Fellow) in 2022, and been chosen as ESI China Highly Cited Scholar for six consecutive years (2013-2019). She has focused on the development of innovative medicinal functional materials, targeted nanodrugs delivery system and cyto-pharmaceuticals. She has presided over more than 40 scientific research projects as group leader, such as National Major Scientific and Technological Special Project for “Significant New Drugs Development”, National Major Scientific and Technological Special Project for “Significant New Drugs Development”, National High Technology Research and Development Program of China (863 Program), National Natural Science Foundation of China (Key Program and General Program). She has published more than 100 SCI papers as the corresponding author in Nat Nanotech, Sci Trans Med, J Am Chem Soc, Angew Chem Int Ed (VIP, cover story), Adv Mater (cover story) and so on. Until now, she has signed 26 authorized invention patents and participated in compiling 4 books.

1. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nature Nanotechnology, 2017, 12(7): 692-700.

2. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Science Translational Medicine. 2020, 12(571): eaaz6667.

3. Enhancing glioblastoma immunotherapy with integrated chimeric antigen receptor T cells through the re-education of tumor-associated microglia and macrophages. ACS Nano. 2024, 18: 11165-11182.

4. Spatiotemporally controlled T-cell combination therapy for solid tumor. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024, 2401100.

5. Sensitizing Tumors to Immune Checkpoint Blockage via STING Agonists Delivered by Tumor-Penetrating Neutrophil Cytopharmaceuticals. ACS nano. 2023, 17(2): 1663-1680.

6. Reprogrammed siTNFα/neutrophil cytopharmaceuticals targeting inflamed joints for rheumatoid arthritis therapy. Acta Pharmaceutica Sinica B. 2023, 13(2): 787-803.

7. New-generation cytopharmaceuticals with powerfully boosted extravasation for enhanced cancer therapy. Journal of Controlled Release. 2023, 359: 116-131.

8. An EPR-Independent Extravasation Strategy: Deformable Leukocytes as Vehicles for Improved Solid Tumor Therapy. Advanced Drug Delivery Reviews. 2022, 187, 114380.

9. Cytopharmaceuticals: An emerging paradigm for drug delivery. Journal of Controlled Release. 2020, 328: 313-324.

10. Transforming Weakness into Strength: Photothermal Therapy-Induced Inflammation Enhanced Cyto-pharmaceutical Chemotherapy as a Combination Anticancer Treatment. Advanced Materials, 2019, 31(5): 1805936.

1. “Imaging the spatiotemporal correlation between the fate of CAR-T cells and the acidic microenvironment in glioma”, supported by the Major Program of National Natural Science Foundation of China, 3.50 million RMB, No. 92159304, 2022.07-2024.07

2. “In vivo spatiotemporal distribution and synergistic immunotherapeutic effect of living cell-based drug delivery systems”, supported by the Key Program of National Natural Science Foundation of China, 2.90 million RMB, No. 82130102, 2022.01-2025.12

3. “Transformative engineering technologies of living cells and creative living cell drugs for solid tumor immunotherapy”, supported by the Frontier Leading Technology Basic Research Special Exploration Program of Natural Science Foundation of Jiangsu Province, 5.00 million RMB, No. BK20212011, 2021.10-2024.09

4. “The regulatory effect and mechanism of engineered neutrophils on tumor immune microenvironment”, supported by the Key Program of National Natural Science Foundation of China, 2.97 million RMB, No. 81930099, 2020.01-2024.12

5. “Funding for the joint laboratory of China Pharmaceutical University & Nanjing Heron Pharmaceutical Science and Technology Co., Ltd.”, supported by Nanjing Heron Pharmaceutical Science and Technology Co., Ltd., 11 million RMB, 2020.11-2026.05

6. “The key technology of neutrophils as targeting carrier for delivery of paclitaxel albumin for glioma postoperative treatment”, supported by the National Major Scientific and Technological Special Project for “Significant New Drugs Development” during “the 13th Five-Year Plan”, 3.19 million RMB, No. 2019ZX09301163, 2019.01-2020.12

7. “Key technologies in accurate diagnosis for glioma”, supported by the National Basic Research Program of China (973 Program), 1.05 million RMB, No. 2015CB755504, 2015.01-2019.12

1. American Institute for Medical and Biological Engineering Fellow, American, 2022

2. ESI China Highly Cited Scholar for 6 consecutive years (2013-2019)

3. Second level for “333 high-level talents training project” from Jiangsu Province, P.R. China, 2011

4. First Prize for natural science, Ministry of Education, P.R. China, 2009

5. Young scientists award noination, Jiangsu Province, P.R. China, 2007

6. First batch of young and middle-aged scientific and technical leaders, for “333 high-level talents training project”, Jiangsu Province, P.R. China, 2007

7. Excellent young backbone teacher, for “blue project”, Jiangsu Province, P. R. China, 2006

8. New Century Excellent Talents in University, Ministry of Education, P. R. China, 2006

9. Third Prize, for progress in science and technology，Jiangsu Province, P. R. China, 2002

Monographs  

1. CY Ju, C Zhang, “Preparation and Characterization of pH Sensitive Drug Liposomes.” Chapter in: WL Lu, XR Qi, “Biomaterial Engineering”. Springer Press, Germany, 2018. (1 Chapter)

2. L Fang, C Zhang, JM Zheng, L Yang, QH Hu, H Xu, G Wei, “Polymer Science in Pharmaceutics (The Fourth Edition)”. China Medical Science and Technology Press, China, 2015. (2 Chapters)  

3. QN Ping, XD Tu, JS Zhang, JB Zhu, LY Zheng, C Zhang, ect., “Pharmacology (The Fourth Edition)”. People's Medical Publishing House, China, 2013. (1 Chapter)  

Translation

1. Hansulich Peterett. “Technical Guide for The Application of Eudragit (Polymethacrylate)”. Translate by QN Ping, C Zhang, etc. Chemical Industry Press, China, 2009.